LivaNova PLC (LIVN) Q3 2026 Earnings Call Transcript
LivaNova PLC (LIVN) Q3 2026 Earnings Call Transcript
Seeking Alpha11/4/2026Neutral
LIVN
LivaNova PLCNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$5.01B
P/E Ratio
26.11
EPS
$3.49
Beta
0.92
52W High
$99.38
52W Low
$49.83
50-Day MA
$79.08
200-Day MA
$73.37
Dividend Yield
—
Profit Margin
13.00%
Forward P/E
19.38
PEG Ratio
0.93
About LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures and sells therapeutic solutions globally. The company is headquartered in London, the United Kingdom.
Fundamentals
| Revenue (TTM) | $1.51B |
| Gross Profit (TTM) | $1.02B |
| EBITDA | $271.27M |
| Operating Margin | 16.70% |
| Return on Equity | 15.50% |
| Return on Assets | 5.11% |
| Revenue/Share (TTM) | $27.48 |
| Book Value | $24.91 |
| Price-to-Book | 3.78 |
| Price-to-Sales (TTM) | 3.33 |
| EV/Revenue | 3.307 |
| EV/EBITDA | 22.83 |
| Quarterly Earnings Growth (YoY) | -78.20% |
| Quarterly Revenue Growth (YoY) | 9.90% |
| Shares Outstanding | $54.93M |
| Float | $54.83M |
| % Insiders | 0.41% |
| % Institutions | 112.75% |
Historical Volatility
HV 10-Day
89.08%
HV 20-Day
64.65%
HV 30-Day
54.05%
HV 60-Day
41.76%
HV Rank
90.5%
Volatility is currently expanding
Analyst Ratings
Consensus ($90.55 target)
3
Strong Buy6
Buy2
HoldLatest News
LivaNova Q3 Earnings Call Highlights
LivaNova NASDAQ: LIVN reported third-quarter 2026 revenue growth of 10% from the prior-year period, driven by double-digit gains in its Cardiopulmonary and epilepsy businesses. The medical technology company raised its full-year revenue and adjusted earnings outlook, citing commercial execution, healthy demand and progress in manufacturing capacity expansion.
MarketBeat11/4/2026Positive
LivaNova (LIVN) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for LivaNova (LIVN) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks Investment Research11/4/2026Positive
LivaNova (LIVN) Surpasses Q3 Earnings and Revenue Estimates
LivaNova (LIVN) came out with quarterly earnings of $1.23 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $1.11 per share a year ago.
Zacks Investment Research11/4/2026Positive
LivaNova Reports Third-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the third quarter ended September 30, 2026 and raised full-year 2026 guidance. Financial Summary and Highlights(1) Third-quarter revenue of $393.1 million increased 9.9% on a reported basis and 10.0% on a constant-currency basis as compared to the prior-year period Third-quarter U.S. GAAP diluted earnings per share of $0.11 and adjusted diluted earnings per.
Business Wire11/4/2026Neutral
Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova's VNS Therapy for Drug-Resistant Epilepsy
GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Neuromodulation: Technology at the Neural Interface has published the full 36-month results from the CORE-VNS study, the first long-term effectiveness evaluation of contemporary VNS Therapy™ devices in people with Drug-Resistant Epilepsy (DRE). The article, “CORE-VNS Seizure and Non-Seizure 36 Month Outcomes in People with Drug-resistant Epilepsy,”1 re.
Business Wire10/23/2026Neutral
LivaNova Director Sells 1,650 Shares for $131,500
The sale was valued at approximately $131,500. The shares traded were equal to 17% of the director's equity stake held directly before the filing.
The Motley Fool9/11/2026Neutral
Artisan International Small-Mid Fund Q2 2026 Portfolio Review
Artisan International Small-Mid Fund portfolio modestly trailed the MSCI ACWI ex USA SMID Index in Q2. On an individual company basis, NICE, Landis+Gyr and DBV Technologies were the largest Q2 detractors. Our top contributors for the quarter were Rohm, LivaNova and Glanbia.
Seeking Alpha8/24/2026Neutral
LivaNova Q2 Earnings & Revenues Beat Estimates, '26 Outlook Raised
LIVN's Q2 earnings and revenues beat estimates as Cardiopulmonary and Epilepsy growth fuels margin gains and a raised 2026 outlook.
Zacks Investment Research8/6/2026Positive
LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcript
LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcript
Seeking Alpha8/5/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on LIVN and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 11/7/2026